Evidence map›Paper›PMID 28731446›Full record

ArticleJournal of Alzheimer's disease : JAD2017

Effect of APOE Genotype on Synaptic Proteins in Earlier Adult Life.

Lindsey I Sinclair, Seth Love

Open access · hybridAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Lindsey I SinclairSchool of Social and Community Medicine, University of Bristol, Oakfield House, Clifton, Bristol, UK.
Seth LoveSchool of Clinical Sciences, University of Bristol, Level 1 Learning and Research Building, Southmead Hospital, Bristol, UK.
Southmead Hospital · GBUniversity of Bristol · GB

Funding

Medical Research Council MC_PC_14095Medical Research Council MR/L022656/1Medical Research Council MR/M024784/1Wellcome Trust
6 · The paper itself

Abstract

backgroundPossession of APOEɛ4 is a strong risk factor for late-onset Alzheimer's disease and is associated with loss of synaptic proteins in the elderly even in the absence of Alzheimer's disease.

objectiveWe hypothesized that ɛ4 allele possession in non-demented adults aged under-75 would also be associated with alterations in the levels of synaptic proteins.

methodsWe measured synaptophysin, PSD95, drebrin, SNAP-25, and septin 7 by ELISA in hippocampus and superior temporal gyrus from 103 adults aged <75 without dementia. Corresponding gene expression was measured by RT-PCR.

resultsThere was no evidence that ɛ4 affected levels of the proteins measured. Instead we found an increase in post-synaptic proteins in the hippocampi of those with an ɛ32 genotype. The evidence was strongest for drebrin (p = 0.011). There was some evidence of increased synaptic protein gene expression in ɛ4 carriers.

conclusionsPeople with an APOEɛ32 genotype have a reduced risk of Alzheimer's disease. It may be relevant that they have a higher level of post-synaptic proteins in the hippocampus even in earlier adulthood.

Indexed as

AdolescentAdultAgedApolipoprotein E4BrainCell Cycle ProteinsCohort StudiesDisks Large Homolog 4 ProteinFemaleGene Expression RegulationGenotypeHumansMaleMiddle AgedNeuropeptidesRNA, MessengerApolipoprotein E4Cell Cycle ProteinsDisks Large Homolog 4 ProteinDLG4 protein, humandrebrinsNeuropeptidesRNA, MessengerSEPTIN7 protein, humanSeptinsSNAP25 protein, humanSynaptophysinSynaptosomal-Associated Protein 25Alzheimer’s diseaseAPOEdementiadrebringeneticspostmortem tissuePSD-95synaptic proteinssynaptophysin

Identifiers

PMID28731446
PMCPMC5545905
OpenAlexW2738979602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.